Pharmaceutical AstraZeneca today announced that the US Food and Drug Administration
has issued a complete response letter (CRL) regarding the supplemental New Drug Application for Farxiga dapagliflozin) as an adjunct treatment to insulin to improve glycemic control in adult patients with type-1 diabetes (T1D), when insulin alone does not provide adequate glycemic control. 15 July 2019